-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 22, 2024

FDA Approves Sotatercept for Pulmonary Arterial Hypertension

Author(s)Marius Hoeper, MD

Marius Hoeper, MD, offers expert perspectives on the recently FDA-approved sotatercept, focusing on its mechanism of action, potential cost implications, and potential advantages and disadvantages it could offer compared with existing foundational therapies.

Episodes in this series

Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension

EP. 1 Evolving Guidelines for PAH Treatment

Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension

EP. 2 New Therapeutic Frontiers in PAH

Ioana Preston, MD, a pulmonologist

EP. 3 Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management

Ioana Preston, MD, a pulmonologist

EP. 4 Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

Marius Hoeper, MD, an expert on PAH

EP. 5 Breaking Down the PAH Cost Burden

Marius Hoeper, MD, an expert on PAH

EP. 6 A New Era in PAH Treatment?

"Clinical Evidence for Emerging PAH Therapies"

EP. 7 Clinical Evidence for Emerging PAH Therapies

"Integrating New PAH Therapies into Clinical Practice"

EP. 8 Integrating New PAH Therapies into Clinical Practice

Ioana Preston, MD, a pulmonologist

EP. 9 Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

Marius Hoeper, MD, an expert on PAH

EP. 10 FDA Approves Sotatercept for Pulmonary Arterial Hypertension

Ronald Oudiz, MD, FACP, FACC, FCCP, an expert on pulmonary arterial hypertension

EP. 11 Overcoming Barriers to Better Patient Outcomes in PAH

Ioana Preston, MD, a pulmonologist

EP. 12 Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

Marius Hoeper, MD, an expert on PAH

EP. 13 Optimizing PAH Care Delivery for Better Outcomes

Marius Hoeper, MD, an expert on PAH

EP. 14 Addressing Unmet Needs in the PAH Landscape

Video content above is prompted by the following question(s):

What is the mechanism of action for the recent FDA-approved drug sotatercept and how does it differ from existing pulmonary arterial hypertension (PAH) therapies?
Given that sotatercept is currently approved as an add-on therapy, what potential cost implications should payers and health systems consider?
Is sotatercept being studied as a foundational therapy for PAH? If so, what potential advantages or disadvantages could it offer compared to existing foundational therapies?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related to this article

FDA approval- jittawit21-stock.adobe.com.jpeg

September 22nd, 2026

FDA Adds HYPERION Data to Sotatercept-csrk Label for Early PAH

HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.

Trending on AJMC

Health System Pharmacies Keep Patients on GLP-1 Therapy

Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote

Melatonin Use Linked to Small REM Sleep Reduction in Children

Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition

Why 4 in 5 Eligible Adults Miss Lung Cancer Screening